Although the majority of MpBCs do not express estrogen receptors (ERs), progesterone receptors (PRs), or human epidermal growth factor receptor 2 (HER2), they are typically more aggressive and less responsive to chemotherapy than conventional triple-negative breast cancers (TNBCs) [1, 3, 4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.